0001193125-26-161507
SEC filingFibroBiologics, Inc. amended its Bylaws on April 16, 2026, to reduce the stockholder quorum requirement for meetings from a majority to one-third of voting power, lowering the threshold needed to conduct business.
The amendment to Section 2.07 of FibroBiologics’ Bylaws modifies a foundational governance threshold: the quorum requirement for stockholder meetings. Previously requiring a majority of voting power, the new standard mandates only one-third — a meaningful reduction that facilitates meeting convening and decision-making, particularly in cases of low stockholder turnout or dispersed ownership. While the filing confirms no changes to adjournment procedures, quorum continuity upon withdrawal, or voting thresholds for specific actions (e.g., director elections remain majority-of-votes-cast under Section 2.09), the lowered quorum may increase the likelihood that proposals proceed without rescheduling. This type of bylaw amendment is typically administrative but carries governance implications for shareholder engagement, proxy contests, and responsiveness to investor initiatives. The change was effected solely by Board action without a shareholder vote, consistent with Delaware law and the Company’s Certificate of Incorporation, and is now codified in Exhibit 3.1, the Second Amended and Restated Bylaws.